Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Andreas Hochhaus, MD, Maria Teresa Gómez Casares, MDPhD, Jesper Stentoft, MD PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Valentin García-Gutiérrez, MD, Norbert Gattermann, MD, Wieslaw Wiktor-Jedrzejczak, MD, Philipp D. Le Coutre, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MB, MD FRCPI, FRCPath, Jerald P. Radich, David M. Ross, MBBS, PhD FRACP, FRCPA, Hans D. Menssen, MD PhD, Weiping Deng, Patricia Brandt, Ari Gnanasakthy, MBA, MSc, Veronique Bedoucha, Giuseppe Saglio, MD

Blood (2016) 128 (22): 3066.

https://doi.org/10.1182/blood.V128.22.3066.3066

Published: 2016

Journal Articles

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Blood (2015) 126 (23): 479.

https://doi.org/10.1182/blood.V126.23.479.479

Published: 2015

Journal Articles

Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Blood (2015) 126 (23): 4054.

https://doi.org/10.1182/blood.V126.23.4054.4054

Published: 2015

Journal Articles

Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study

Blood (2013) 122 (21): 4030.

https://doi.org/10.1182/blood.V122.21.4030.4030

Published: 2013

Journal Articles

A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose

Vincen t Ribrag, Claire N Harrison, DM, FRCP, FRCPath, Florian H Heidel, MD, Jean-Jacques Kiladjian, MD, PhD, Suddhasatta Acharyya, PhD, Song Mu, PhD, Tracy Liu, Denise Williams, MD, Francis J Giles, MB, MD, FRCPI, FRCPath, Eibhlin Conneally, MB, MRCPI, FRCPath, PhD, Thomas Kindler, MD, Francesco Passamonti, MD, Alessandro M Vannucchi, MD

Blood (2013) 122 (21): 4045.

https://doi.org/10.1182/blood.V122.21.4045.4045

Published: 2013

Journal Articles

Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,

Blood (2011) 118 (21): 3770.

https://doi.org/10.1182/blood.V118.21.3770.3770

Published: 2011

Journal Articles

Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Francis J. Giles, MB, MD, FRCPI, FRCPath, Michael J. Mauro, MD, Frank Hong, MD, PhD, MPH, Christine-Elke Ortmann, Richard C. Woodman, Philipp D. LeCoutre, MD, Giuseppe Saglio, MD

Blood (2011) 118 (21): 2757.

https://doi.org/10.1182/blood.V118.21.2757.2757

Published: 2011

Journal Articles

A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission

Francis J. Giles, MB, MD, FRCPI, FRCPath, Gianantonio Rosti, MD, Gert Ossenkoppele, MD, PhD, Michel Tulliez, Jesper Stentoft, MD, PhD, Aristoteles Giagounidis, MD, Francesco Nobile, MD, Philipp D. le Coutre, MD, Norbert Gattermann, MD, Laimonas Griskevicius, Nicholas C.P. Cross, PhD, FRCPath, Sarah Hill, BSc (hons), PhD, MICR, Peter Schuld, PhD, Angela Pellegrino, Domenico Magazzù, Andreas Hochhaus, MD

Blood (2011) 118 (21): 2759.

https://doi.org/10.1182/blood.V118.21.2759.2759

Published: 2011

Journal Articles

Targeting Pim Kinase Activity with the Novel Small Molecule Inhibitor SGI-1776 Significantly Augments the Efficacy of Cytarabine In Models of Acute Myeloid Leukemia

Kevin R Kelly, MD, Kelli Oberheu, B.S., Ernest Medina, B.S., Claudia M Espitia, MS, Devalingam Mahalingam, MD, PhD, Pietro Taverna, PhD, Gavin S. Choy, PharmD, MBA, Steffan T Nawrocki, PhD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Jennifer S Carew, PhD

Blood (2010) 116 (21): 3253.

https://doi.org/10.1182/blood.V116.21.3253.3253

Published: 2010

Journal Articles

Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR.

Eibhlin Conneally, MB, MRCPI, FRCPath, PhD, Ronan T Swords, MD, MRCPI, FRCPath, Francis J. Giles, MB, MD, FRCPI, FRCPath, Mary Frances McMullin, MD, Philipp le Coutre, Stephen Langabeer, Marzena Wieczorkowska, Cliona McDowell, Brian Moulton, Karine Egan, Michael O'Dwyer, MD, FRCPath

Blood (2010) 116 (21): 3427.

https://doi.org/10.1182/blood.V116.21.3427.3427

Published: 2010

Journal Articles

A New Rotary Powered Device for Bone Marrow Aspiration and Biopsy Yields Superior Specimens with Less Pain: Results of a Randomized Clinical Study

Ronan Swords, MD, MRCPI, FRCPath, Javier Anguita, MD, Russell A. Higgins, MD, Andrea Yunes, MD, Michael Naski, MD, PhD, Swaminathan Padmanabhan, MD, Kevin R Kelly, MD, Devalingam Mahalingam, MD, PhD, Thomas Philbeck, PhD, Larry Miller, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Marsha Kinney, MD, Andrew Brenner, MD

Blood (2010) 116 (21): 1529.

https://doi.org/10.1182/blood.V116.21.1529.1529

Published: 2010

Journal Articles

Nilotinib Exposure-Response Analysis In Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML)

Francis J. Giles, MB, MD, FRCPI, FRCPath, Ophelia Yin, PhD, FCP, Yen Lin Chia, PhD, Philipp D. le Coutre, MD, Richard C. Woodman, MD, Oliver G. Ottmann, MD, Michele Baccarani, MD, Hagop M. Kantarjian, MD

Blood (2010) 116 (21): 890.

https://doi.org/10.1182/blood.V116.21.890.890

Published: 2010

Journal Articles

The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study

Ronan T Swords, MD, MRCPI, FRCPath, Harry P Erba, MD, PhD, Daniel J DeAngelo, MD, PhD, Peter G Smith, PhD, Michael D Pickard, MA, Bruce J. Dezube, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Bruno C. Medeiros, MD

Blood (2010) 116 (21): 658.

https://doi.org/10.1182/blood.V116.21.658.658

Published: 2010

Journal Articles

A Phase II Multicentre Study with Elacytarabine as Second Salvage Therapy in Patients with AML.

Susan O'Brien, M.D., David A. Rizzieri, MD, Norbert Vey, Farhad Ravandi, Utz O. Krug, Mikkael A. Sekeres, MD, MS, Mike Dennis, Adriano Venditti, MD, Tove Flem Jacobsen, Karin Staudacher, Bo I Nilsson, MD, PhD, Francis J. Giles, MB, MD, FRCPI, FRCPath

Blood (2009) 114 (22): 1042.

https://doi.org/10.1182/blood.V114.22.1042.1042

Published: 2009

Journal Articles

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

Hagop M. Kantarjian, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Kapil N. Bhalla, MD, Javier Pinilla-Ibarz, MD, PhD, Richard A. Larson, MD, Norbert Gattermann, MD, PhD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD, Jerald P. Radich, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD, MBBS, Giovanni Martinelli, MD, Dong-Wook Kim, MD, PhD, Yaping Shou, MD, PhD, Neil J. Gallagher, MD, PhD, Jim Wang, PhD, Jorge Cortes-Franco, MD, Michele Baccarani, MD, Philipp D. le Coutre, MD

Blood (2009) 114 (22): 1129.

https://doi.org/10.1182/blood.V114.22.1129.1129

Published: 2009

Journal Articles

The Novel Orally Active Aurora A Kinase Inhibitor MLN8237 Is Highly Active in Preclinical Models of Acute Myeloid Leukemia and Significantly Increases the Efficacy of Cytarabine.

Kevin R. Kelly, MD, Ronan T. Swords, M.D., Devalingam Mahalingam, M.D., Steffan T. Nawrocki, PhD, Ernest Medina, B.S., Sabrina Smith, Swaminathan Padmanabhan, MD, MBBS, Jeffrey Ecsedy, Mary R Cahill, FRCPI, FRCPath, Francis J. Giles, MB, MD, FRCPI, FRCPath, Jennifer S. Carew, Ph.D.

Blood (2009) 114 (22): 2087.

https://doi.org/10.1182/blood.V114.22.2087.2087

Published: 2009

Journal Articles

Use of a New Rotary Powered Device for Bone Marrow Aspiration and Biopsy Yields Excellent Specimens Quickly and Efficiently.

Ronan T. Swords, MD, MRCPI, FRCPath, Kevin R. Kelly, MD, MRCPI, FRCPath, Devalingam Mahalingam, MD, PhD, Stephen C. Cohen, MD, Larry J. Miller, MD, Thomas E. Philbeck, Jr., PhD, MBA, Sander O. Hacker, VMD, DACLAM, Cathy J. Spadaccini, MD, Andrew Brenner, MD, PhD, Francis J. Giles, MB, MD, FRCPI, FRCPath

Blood (2009) 114 (22): 4544.

https://doi.org/10.1182/blood.V114.22.4544.4544

Published: 2009

Journal Articles

Impact of Allogeneic Stem Cell Transplantation as Salvage Therapy After T315I Mutation Detection in Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients.

Franck Emmanuel Nicolini, MD, PhD, Wei Zhou, MD, PhD, Giovanni Martinelli, MD, Michael J. Mauro, MD, Andreas Hochhaus, MD, Jing Su, MS, Jane Apperley, MD, Charles Chuah, MD, Inge Dufva, MD, Dong-Wook Kim, MD, PhD, Francis J. Giles, MB,MD,FRCPI,FRCPath, Senaka Peter, MPH, Jorge Cortes, MD

Blood (2009) 114 (22): 645.

https://doi.org/10.1182/blood.V114.22.645.645

Published: 2009

Journal Articles

A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).

Swaminathan Padmanabhan, MD, MBBS, Joseph Thaddeus Beck, MD, Kevin R. Kelly, MD, Nikhil C. Munshi, MD, Andy Dzik-Jurasz, Esha Gangolli, Seth Ettenberg, Kelly Miner, Sanela Bilic, Winston Whyte, Fazal Mehdi, Lu-May Chiang, Patricia Liz Rae, BSc, Andrew Spencer, Jatin Shah, MD, Kenneth C. Anderson, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, A. Keith Stewart, MBChB

Blood (2009) 114 (22): 750.

https://doi.org/10.1182/blood.V114.22.750.750

Published: 2009

Journal Articles

Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data.

Hagop M. Kantarjian, MD, Elias Jabbour, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Kapil N. Bhalla, MD, Javier Pinilla-Ibarz, MD, PhD, Richard A. Larson, MD, Norbert Gattermann, MD, PhD, Oliver G. Ottmann, MD, Jim Wang, PhD, Richard C. Woodman, MD, Michele Baccarani, MD, Philipp D. le Coutre, MD, Jorge Cortes, MD

Blood (2009) 114 (22): 3298.

https://doi.org/10.1182/blood.V114.22.3298.3298

Published: 2009

NARROW

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study

A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose

Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,

Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission

Targeting Pim Kinase Activity with the Novel Small Molecule Inhibitor SGI-1776 Significantly Augments the Efficacy of Cytarabine In Models of Acute Myeloid Leukemia

Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR.

A New Rotary Powered Device for Bone Marrow Aspiration and Biopsy Yields Superior Specimens with Less Pain: Results of a Randomized Clinical Study

Nilotinib Exposure-Response Analysis In Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML)

The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study

A Phase II Multicentre Study with Elacytarabine as Second Salvage Therapy in Patients with AML.

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

The Novel Orally Active Aurora A Kinase Inhibitor MLN8237 Is Highly Active in Preclinical Models of Acute Myeloid Leukemia and Significantly Increases the Efficacy of Cytarabine.

Use of a New Rotary Powered Device for Bone Marrow Aspiration and Biopsy Yields Excellent Specimens Quickly and Efficiently.

Impact of Allogeneic Stem Cell Transplantation as Salvage Therapy After T315I Mutation Detection in Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients.

A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).

Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only